KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib,Clinical Genetics

当前位置： X-MOL 学术 › Clin. Genet. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib
Clinical Genetics ( IF 2.9 ) Pub Date : 2021-06-30 , DOI: 10.1111/cge.14018
Clara Lacasta-Plasin ₁ , Victor Martinez-Glez _{2,

3} , Lara Rodriguez-Laguna _{2,

3} , Antonio Cervantes-Pardo ₄ , Teresa Martinez-Menchon ₅ , Regina Sanchez-Jimenez ₄ , Minia Campos-Dominguez _{1,

5,

6}

Affiliation

Detection of KRAS mutation in skin biopsy in a patient with melorheostosis, lymphantiomatosis and vascular stenosis. She was successfully treated with trametinib.